| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Neurogene Inc. (NGNE) has 3 insiders with recent SEC Form 4 filings, including 81 buys and 5 sells. NGNE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.34M | $42.39M | - | |
| CFO | 98.4K | $3.10M | - | |
| Other | 12.5K | $393.2K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 14, 2018 | Levitt Daniel J | Director | Sale+OE | 3,906 | $12.67 | $49,489.02 | -100% | |
| Mar 15, 2018 | MacKenzie Lloyd | Chief Operating Officer | Sale+OE | 1,302 | $14.63 | $19,048.78 | -100% | |
| Jun 5, 2017 | Main David | President And CEO | Sale+OE | 15,625 | $13.26 | $207,243.74 | -6.8% | |
| Jan 9, 2017 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 398,062 | $17.18 | $6,836,812.66 | +0.4% | |
| Sep 20, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 2,783,605 | $12.25 | $34,110,452.49 | +31.4% | |
| Mar 16, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 471,667 | $7.99 | $3,770,636.35 | +1.3% | |
| Jan 26, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 140,786 | $10.80 | $1,520,909.21 | +0.2% | |
| Jan 20, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 190,079 | $9.33 | $1,773,653.44 | +0.4% | |
| Jan 15, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 202,623 | $8.28 | $1,677,083.14 | +0.4% | |
| Sep 10, 2015 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 2,480,032 | $15.50 | $38,440,496.00 | +58.1% |